{
    "nctId": "NCT03075072",
    "briefTitle": "Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial",
    "officialTitle": "Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation (SRS) in Patients With 5-20 Brain Metastases: A Phase III, Randomized Clinical Trial",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Brain Metastases",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 196,
    "primaryOutcomeMeasure": "Quality of Life Survey (symptoms and interference)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Participants must have a biopsy proven solid malignancy with untreated (by radiation) intracranial lesions radiographically consistent with or pathologically proven to be brain metastases. Patients who have undergone prior systemic therapy are eligible\n* Five-twenty intracranial lesions must be present on MRI of the brain\n* Age 18-80 years at diagnosis of brain metastases\n* Karnofsky performance status of at least 70\n\nExclusion Criteria:\n\n* Participants who have undergone prior radiation for brain metastases.\n* Patients who have undergone resection of one or more brain metastases but who have not yet started adjuvant radiotherapy are eligible for the study\n* Participants who cannot undergo a brain MRI\n* Participants who cannot receive gadolinium (MRI contrast)\n* Participants with stage IV-V chronic kidney disease or end stage renal disease\n* Participants with widespread, definitive leptomeningeal disease\n* Participants with small cell lung cancer, lymphoma, or myeloma\n* Participants with a maximum tumor diameter exceeding 5 cm (if not resected)",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}